Last Updated: November 16, 2026

Litigation Details for Cephalon Inc. v. Watson Pharmaceuticals Inc. (D. Del. 2009)

« Back to Dashboard


Small Molecule Drugs cited in Cephalon Inc. v. Watson Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Cephalon Inc. v. Watson Pharmaceuticals Inc. Litigation Summary, 1:09-cv-00724

Last updated: November 16, 2026

Cephalon Inc. v. Watson Pharmaceuticals Inc., No. 1:09-cv-00724, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Watson’s abbreviated new drug application for a generic version of Cephalon’s Fentora, an orally disintegrating fentanyl buccal tablet. Cephalon asserted formulation and drug-delivery patents covering Fentora. The case was part of Cephalon’s broader strategy to delay generic entry for its opioid product through Orange Book patent enforcement.

What drug and patents were involved in Cephalon v. Watson?

The dispute concerned Fentora, a fentanyl buccal tablet marketed by Cephalon for breakthrough cancer pain in opioid-tolerant patients.

Item Details
Brand drug Fentora
Active ingredient Fentanyl citrate
Dosage form Buccal tablet designed for rapid oral transmucosal delivery
Regulatory pathway Watson ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Court U.S. District Court for the District of Delaware
Civil action No. 1:09-cv-00724
Plaintiff Cephalon Inc.
Defendant Watson Pharmaceuticals Inc.
Litigation type Hatch-Waxman patent infringement action
Principal technology Effervescent and transmucosal delivery of fentanyl

Cephalon’s complaint followed Watson’s Paragraph IV certification that the relevant Orange Book-listed patents were invalid, unenforceable, or would not be infringed by Watson’s proposed product. The Paragraph IV notice created a statutory basis for suit under 35 U.S.C. § 271(e)(2).

The case centered on patents associated with Cephalon’s Fentora delivery platform, including U.S. Patent No. 6,200,604 and U.S. Patent No. 6,974,590. The asserted claims addressed compositions and methods that used effervescence or related tablet characteristics to improve drug absorption across the oral mucosa. The precise claims in dispute depended on the procedural stage and claim-construction record.

What patents protect Fentora?

Fentora’s patent estate included patents directed to the product’s formulation, dosage form, and transmucosal delivery method rather than fentanyl as a molecule.

U.S. Patent No. 6,200,604

The '604 patent covered effervescent dosage forms and related drug-delivery technology. Its importance was tied to the use of an effervescent formulation to promote rapid absorption through the buccal mucosa.

The patent was relevant because Watson’s proposed generic product would have to reproduce the core technical characteristics of Fentora to obtain approval as a pharmaceutical equivalent or therapeutically substitutable product. Cephalon therefore used the formulation patent as a principal barrier to generic entry.

U.S. Patent No. 6,974,590

The '590 patent also addressed pharmaceutical compositions using effervescent technology. Cephalon asserted that Watson’s proposed product would practice patented features of the Fentora formulation and delivery system.

The asserted patent claims raised standard Hatch-Waxman issues:

  • Claim construction for effervescent components and dosage-form limitations.
  • Literal infringement and infringement under the doctrine of equivalents.
  • Anticipation by earlier transmucosal and effervescent formulations.
  • Obviousness based on known fentanyl delivery systems and oral dosage technologies.
  • Enablement and written-description issues.
  • The effect of any prosecution-history disclaimer.
  • Whether the ANDA product, rather than the commercial product actually sold by Watson, would infringe.

Orange Book listing and patent scope

The Fentora patents were product-specific and formulation-oriented. They did not confer exclusivity over fentanyl generally. A competing company could seek approval for a different dosage form, route of administration, or formulation if it avoided the listed claims and satisfied FDA requirements.

The commercial value of the patents depended on whether a generic manufacturer could design around:

  1. The effervescent system.
  2. The particle-size and excipient profile.
  3. The tablet’s disintegration and dissolution characteristics.
  4. The transmucosal absorption mechanism.
  5. The claimed method of administering fentanyl to opioid-tolerant patients.

Why did Cephalon sue Watson under Hatch-Waxman?

Cephalon sued after Watson filed an ANDA containing Paragraph IV certifications against Fentora patents. Under the Hatch-Waxman framework, the filing of an ANDA with a Paragraph IV certification is an artificial act of infringement under Section 271(e)(2), even before a commercial launch occurs.

The litigation gave Cephalon the opportunity to obtain a 30-month stay of FDA approval, subject to the statutory requirements and any applicable regulatory developments. The suit also shifted the dispute from a future market-entry challenge to an immediate federal patent case.

Watson’s legal position would have been that:

  • The asserted claims were invalid, particularly for obviousness.
  • The proposed product did not satisfy one or more claim limitations.
  • The patent claims should be narrowly construed.
  • The patents did not lawfully block approval of Watson’s ANDA.
  • Any settlement or exclusivity arrangement had to be assessed under antitrust and pharmaceutical-settlement standards.

What were the principal legal issues?

Claim construction

The litigation required the court to define technical terms involving effervescence, oral transmucosal delivery, tablet composition, and drug absorption. Claim construction was commercially significant because minor differences in excipients, manufacturing processes, or dosage-form behavior could determine infringement.

A broad construction would strengthen Cephalon’s ability to block competing formulations. A narrow construction would increase the feasibility of a design-around product.

Obviousness

Watson’s strongest invalidity theory was likely obviousness under 35 U.S.C. § 103. The relevant prior art included:

  • Fentanyl buccal and sublingual delivery systems.
  • Effervescent pharmaceutical tablets.
  • Oral transmucosal dosage forms.
  • Known methods for improving mucosal drug absorption.
  • Earlier opioid-delivery technologies.

The key question was whether a skilled pharmaceutical formulator would have had a reason to combine those teachings with a reasonable expectation of success. Cephalon’s response would focus on formulation unpredictability, the specific performance of the Fentora dosage form, and any unexpected pharmacokinetic or absorption benefits.

Infringement

Infringement analysis focused on the product described in Watson’s ANDA. The court would compare the ANDA’s formulation and manufacturing specifications with the asserted patent claims.

For a formulation patent, discovery typically includes:

  • Active and inactive ingredients.
  • Ingredient concentrations.
  • Particle-size distribution.
  • Tablet manufacturing parameters.
  • Dissolution and disintegration data.
  • Stability data.
  • Bioequivalence protocols.
  • Manufacturing-site information.
  • FDA correspondence concerning the proposed generic.

Written description and enablement

Watson could challenge whether Cephalon’s patent disclosures adequately supported the breadth of the asserted claims. This issue is particularly relevant where a patent claims a broad class of formulations but provides examples covering only a limited number of compositions.

The enablement issue would ask whether the patent enabled the full scope of the claims without undue experimentation. Cephalon would rely on the predictable aspects of pharmaceutical formulation and the working examples disclosed in the patents.

Enforceability and inequitable conduct

As in many pharmaceutical patent cases, the prosecution record could create an inequitable-conduct issue. Watson would need clear and convincing evidence that material information was withheld or misrepresented with the specific intent to deceive the U.S. Patent and Trademark Office. A mere failure to disclose prior art would not be sufficient after the Federal Circuit’s higher pleading and proof requirements.

What was the litigation timeline?

Date or period Event
2009 Watson filed an ANDA seeking approval for a generic Fentora product and served Paragraph IV certifications.
2009 Cephalon filed Civil Action No. 1:09-cv-00724 in the District of Delaware.
2010-2011 The parties litigated claim construction, infringement, invalidity, and related discovery issues.
2011 onward Fentora patent disputes continued within Cephalon’s broader generic-challenge and settlement program.
Later period The case was resolved through the Delaware federal-court docket rather than by a publicly reported appellate merits decision comparable to Cephalon’s Provigil litigation.

The docket should be distinguished from Cephalon’s separate modafinil litigation involving Provigil. The prominent Federal Circuit decision in Cephalon’s Provigil cases concerned different patents, products, and litigation records. It should not be treated as the merits disposition of the Watson Fentora action.

Was Watson’s Paragraph IV challenge successful?

The case did not produce a widely cited Federal Circuit merits decision holding that Watson had invalidated the Fentora patents. The commercially relevant result was therefore not a reported appellate invalidity judgment against Cephalon.

The absence of a precedential appellate ruling does not mean that the patents were necessarily upheld on every claim. It means that the public litigation record does not establish a broad Federal Circuit holding invalidating the Fentora patent estate based on Watson’s challenge.

For generic-entry analysis, the practical questions were:

  • Whether FDA approval remained blocked during the statutory litigation stay.
  • Whether Watson obtained a settlement-based launch date.
  • Whether the settlement included a license or other authorized-entry mechanism.
  • Whether Watson could launch an authorized generic or an alternative formulation.
  • Whether later patents created a second barrier after the original patents expired.

Did the case involve a biosimilar challenge?

No. Fentora is a small-molecule fentanyl product, and Watson’s product was pursued through the ANDA pathway. Biosimilar procedures under the Biologics Price Competition and Innovation Act were not relevant.

The competitive risks were generic-drug risks:

  • Paragraph IV litigation.
  • ANDA approval timing.
  • 180-day first-filer exclusivity.
  • Formulation design-around.
  • Authorized-generic competition.
  • State substitution laws.
  • Controlled-substance regulatory requirements.

What was the regulatory status of Fentora?

Fentora was approved by the FDA as a transmucosal fentanyl product for breakthrough cancer pain in opioid-tolerant patients. Because fentanyl is a controlled substance, a generic entrant would face both ordinary ANDA requirements and controlled-substance compliance obligations.

Relevant regulatory barriers included:

  • Demonstration of pharmaceutical equivalence.
  • Bioequivalence.
  • Consistent tablet performance.
  • Dose proportionality and titration considerations.
  • Risk-management requirements for transmucosal immediate-release fentanyl products.
  • Manufacturing controls for a potent opioid.
  • Diversion and abuse-prevention controls.

FDA approval of an ANDA would not itself resolve patent infringement. FDA approval and patent clearance are separate legal questions. A generic applicant could obtain approval but remain subject to launch restrictions created by patents, settlement terms, or court orders.

How strong was Cephalon’s Fentora patent estate?

Cephalon’s Fentora estate had moderate commercial strength because it protected the delivery platform rather than the underlying fentanyl molecule.

Strengths

  • The patents covered a clinically differentiated dosage form.
  • The product required specialized transmucosal formulation technology.
  • Bioequivalence could be more difficult than for a conventional oral tablet.
  • Manufacturing and performance specifications were closely linked to infringement analysis.
  • Fentora’s controlled-substance status increased manufacturing and distribution complexity.

Weaknesses

  • The underlying active ingredient, fentanyl, was not protected by the formulation patents.
  • Effervescent dosage technology had substantial prior-art exposure.
  • A competing manufacturer could pursue a formulation design-around.
  • Patent scope depended heavily on claim construction.
  • The commercial value of the patents declined as expiration approached.
  • Additional patents could face separate validity challenges.

The strongest protection was concentrated in formulation and delivery claims. The estate was less resilient than a patent estate that combined composition-of-matter, crystal-form, formulation, method-of-use, manufacturing, and device claims.

What generic entry risks did Cephalon face?

Cephalon faced several generic-entry scenarios.

Scenario Commercial effect
Cephalon prevailed on validity and infringement Watson’s launch could be delayed until patent expiration or a negotiated date.
Watson prevailed on all material claims Immediate generic-entry risk would increase, subject to FDA approval and regulatory exclusivity.
Watson won on some claims but lost on others Launch timing would depend on the surviving claims and any court injunction.
Watson designed around the asserted claims A noninfringing generic could enter without invalidating the patents.
Settlement permitted licensed entry Competition would begin on the negotiated settlement date.
Authorized generic launched Cephalon could preserve supply-chain participation while limiting the price impact of independent generic entry.

For an opioid product, substitution and market access would also depend on pharmacy distribution, controlled-substance quotas, wholesaler participation, and payer formulary treatment.

Did the case affect Cephalon’s broader commercial strategy?

Yes. Fentora was one component of Cephalon’s broader strategy to protect branded revenue through formulation patents, method-of-use patents, and settlements with ANDA filers. Cephalon’s approach relied on extending market protection beyond the active ingredient through product-specific delivery technology.

The company’s patent strategy had three commercial objectives:

  1. Delay direct generic substitution.
  2. Preserve pricing for the branded product.
  3. Convert litigation risk into negotiated launch dates or licenses.

The economic exposure depended on Fentora sales, the number of potential ANDA filers, the first-filer position, and the ability of later generic applicants to avoid the asserted patents.

What is the current legal significance of Cephalon v. Watson?

The case is significant as an example of formulation-patent litigation involving an orally transmucosal opioid product. Its main analytical lessons are:

  • A branded company can use formulation patents to protect a product after active-ingredient protection has weakened.
  • Paragraph IV litigation can delay competition without producing a broad appellate ruling.
  • Patent strength depends on claim breadth, technical reproducibility, and the availability of design-arounds.
  • FDA approval, Orange Book listing, and patent enforceability must be analyzed separately.
  • Controlled-substance products carry manufacturing and distribution barriers that can reinforce, but do not replace, patent protection.
  • A settlement may determine actual entry timing even when the reported opinions do not resolve every patent issue.

Key Takeaways

  • Cephalon v. Watson, No. 1:09-cv-00724, was a Delaware Hatch-Waxman case involving generic Fentora.
  • The dispute concerned Cephalon’s effervescent and transmucosal fentanyl formulation technology.
  • The principal patents included U.S. Patent Nos. 6,200,604 and 6,974,590.
  • Watson’s Paragraph IV ANDA challenge triggered patent litigation under 35 U.S.C. § 271(e)(2).
  • The case did not generate a widely cited Federal Circuit decision invalidating Cephalon’s Fentora patents.
  • The patents protected formulation and delivery technology, not fentanyl generally.
  • Fentora faced generic-entry risk through invalidity claims, design-around formulations, settlement entry, and later patent challenges.
  • Biosimilar law was not relevant because Fentora is a small-molecule drug.
  • The commercial value of Cephalon’s estate depended on formulation complexity, FDA approval timing, Orange Book listings, and settlement terms.

Frequently Asked Questions

What product was at issue in Cephalon v. Watson 1:09-cv-00724?

The case concerned Watson’s proposed generic version of Fentora, Cephalon’s fentanyl buccal tablet for breakthrough cancer pain in opioid-tolerant patients.

Was Cephalon v. Watson a Provigil patent case?

No. The docket concerned Fentora-related patent issues. Cephalon’s Provigil modafinil litigation involved separate actions and different patents.

Did Watson launch a generic Fentora product immediately after the case?

The public record does not establish a broad immediate launch resulting from a reported merits victory by Watson. Entry timing depended on the litigation resolution, FDA approval, patent status, and any settlement restrictions.

Were Fentora patents listed in the FDA Orange Book?

Yes. Cephalon relied on Orange Book-listed patents covering Fentora’s formulation and delivery technology.

Can a generic fentanyl product avoid Cephalon’s Fentora patents?

Potentially. A manufacturer could pursue a formulation or delivery system that avoided the asserted claim limitations, although it would still need to satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.

References

  1. Cephalon Inc. v. Watson Pharmaceuticals Inc., No. 1:09-cv-00724, U.S. District Court for the District of Delaware docket.

  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

  3. 21 U.S.C. § 355. Abbreviated applications for new drugs.

  4. 35 U.S.C. § 271(e)(2). Infringement based on submission of an abbreviated new drug application.

  5. U.S. Patent No. 6,200,604. Effervescent dosage forms.

  6. U.S. Patent No. 6,974,590. Cephalon fentanyl transmucosal delivery technology.

  7. Federal Trade Commission. (2013). Pay-for-delay: How drug company pay-offs cost consumers billions. Federal Trade Commission.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.